Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  Astellas Pharma Inc    4503   JP3942400007

ASTELLAS PHARMA INC (4503)
My previous session
Most popular
  Report  
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Astellas Pharma : buys Potenza Therapeutics for up to $405m

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/18/2018 | 03:50am EST

Japanese pharmaceutical company Astellas Pharma has acquired US-based Potenza Therapeutics for a total consideration of up to $405m.

The deal is made possible as Astellas exercised its option to buy Potenza Therapeutics under a collaboration agreement signed in 2015 for the development of new immuno-oncology (IO) therapies.

Astellas made an upfront payment of $164.6m; Potenza will be eligible for additional payment of up to $240.1m dependent on the progress of different programmes in clinical development.

Following the completion of the transaction, Potenza has become a wholly-owned subsidiary of Astellas.

Astellas Pharma president and CEO Kenji Yasukawa said: In oncology, Astellas has focused on developing treatments for unmet medical needs with novel mechanisms of action and modalities.

We believe the novel assets we have developed with Potenza have the potential to make an even more pronounced difference for patients in need.

Over their alliance period, Astellas and Potenza discovered and developed three investigational new drugs (INDs) ASP8374/PTZ-201, ASP1948/PTZ-329 and ASP1951/PTZ-522.

The drug candidates are said to have the potential to treat a variety of cancers non-responsive or resistant to the current generation of IO therapies.

ASP8374/PTZ-201 is an immune checkpoint inhibitor, while ASP1948/PTZ-329 inhibits Treg function. Both the compounds are undergoing Phase I clinical trials.

ASP1951/PTZ-522 is a GITR agonistic antibody that holds investigational new drug clearance.

Potenza Therapeutics president and CEO Dan Hicklin said: Over the past three and a half years, we have enjoyed a successful and productive partnership with Astellas.

I am pleased that these therapies will now have access to the resources of a large international company, with world-class R&D and the strategic and financial backing to support the development of these innovative potential new medicines for cancer patients in need.

The clinical IO therapies resulting from the partnership are expected to enable combinations with Astellas existing non-IO programmes for life cycle management and future IO combinations.

(c) 2018 TehranTimes. All Rights Reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTELLAS PHARMA INC
01/18ASTELLAS PHARMA INC. : - Transfer of Sale and Distribution, and Termination of C..
AQ
01/18ACTINIUM PHARMACEUTICALS : Successfully Completes First Module of Collaborative ..
AQ
01/18ACTINIUM PHARMACEUTICALS : Successfully Completes First Module of Collaborative ..
AQ
01/11ASTELLAS PHARMA : Announces Key Senior Leadership Promotions and New Hire in Med..
AQ
01/10AMGEN ASTELLAS BIOPHARMA K.K - EVENITY SUBCUTANEOUS INJECTION 105mg SYRINGE R..
AQ
01/09Amgen - EVENITY Receives Approval in Japan for the Treatment of Osteoporosis ..
AQ
01/09ASTELLAS PHARMA : Announces Approval in Japan for the treatment of prostate canc..
AQ
01/09CYTOMX THERAPEUTICS : Acquires Agensys CD3-based Bispecific Technologies
AQ
2018ASTELLAS PHARMA : and Pfizer Announce Positive Top-Line Results from Phase 3 ARC..
AQ
2018ASTELLAS PHARMA : buys Potenza Therapeutics for up to $405m
AQ
More news
Financials (JPY)
Sales 2019 1 302 B
EBIT 2019 270 B
Net income 2019 207 B
Finance 2019 373 B
Yield 2019 2,49%
P/E ratio 2019 14,35
P/E ratio 2020 15,06
EV / Sales 2019 2,09x
EV / Sales 2020 2,07x
Capitalization 3 092 B
Chart ASTELLAS PHARMA INC
Duration : Period :
Astellas Pharma Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTELLAS PHARMA INC
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 13
Average target price 1 968  JPY
Spread / Average Target 26%
EPS Revisions
Managers
NameTitle
Kenji Yasukawa President, CEO & Representative Director
Yoshihiko Hatanaka Chairman
Chikashi Takeda Chief Financial Officer
Mitsunori Matsuda General Manager-Pharmaceutical Technology
Tomokazu Fujisawa Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC13.11%28 160
JOHNSON & JOHNSON1.27%350 508
PFIZER-2.57%246 674
NOVARTIS5.66%227 840
ROCHE HOLDING LTD.6.16%223 498
MERCK AND COMPANY-0.71%197 291